We want every man with prostate cancer – or at risk of it – to have access to the same high-quality diagnosis, treatment and support, no matter where in the UK he lives. In a complex and pressured health service, we know clinicians are the key to driving improvement.
This programme is for those working along the prostate cancer pathway to develop their skills and knowledge to implement a stratified follow up pathway locally for men who have had treatment for their prostate cancer.
If you have specific queries about the Improvement Programmes, please email email@example.com.
Application deadline: 5pm Friday 10 January 2020
This programme will be designed to work in parallel with a busy clinical schedule and is carefully planned to deliver maximum value in a minimum time span.
Module 1: Thursday 13 and Friday 14 February 2020 (residential)
Module 2: Thursday 12 March 2020
Please ensure you are able to attend all 3 days prior to application
Registration will open at 10.00am on Thursday 13 February and the day will be followed by a drinks reception and dinner. The programme will recommence at 8.30am on Friday 14 February and will conclude at 2pm.
On Thursday 12 March the programme will commence at 10.30am and conclude at 4pm.
Central London, venue to be confirmed.
Accommodation and travel
If required accommodation will be provided near the venue for the night of Thursday 13 February 2020. Please note travel expenses are not reimbursable.
The aim of this programme will address the challenges around implementing the TrueNTH Supported Self-Management and Follow-up Care model and equip you with the skills and knowledge to drive the implementation of this locally
This programme will focus on supporting you through:
- Leadership and change management theory
- Opportunity to put this theory into practice
- Peer learning and sharing best practice
- Coaching and support
- Networking and hearing from inspirational leaders
- Support to develop an improvement plan
The Prostate Cancer Improvement Programmes have been supported by grants from Astellas Pharma Ltd, Bayer UK, BTG - now part of Boston Scientific, Roche Products Ltd. and Sanofi Genzyme. None of these organisations have had any control over the educational content of this activity.